Details for Patent: 9,750,711

Which drugs does patent 9,750,711 protect, and when does it expire?

Patent 9,750,711 protects ABSORICA LD and is included in one NDA.

This patent has eight patent family members in eight countries.

Summary for Patent: 9,750,711

Title:	Low dose oral pharmaceutical composition of isotretinoin
Abstract:	The present invention provides a low dose oral pharmaceutical composition of isotretinoin having reduced food effect, in particular no food effect. The present invention further relates to a process for preparing the oral pharmaceutical composition of the present invention.
Inventor(s):	Madan; Harish Kumar (Haryana, IN), Venkateshwaran; Rathinasabapathy (Tamil Nadu, IN), Madan; Sumit (Delhi, IN), Kochhar; Ravi (Haryana, IN)
Assignee:	Sun Pharmaceutical Industries Limited (Mumbai, IN)
Application Number:	15/444,571
Patent Claim Types: see list of patent claims	Composition; Formulation; Device; Dosage form;
Scope and claims summary:	US Patent 9750711: Analysis of Scope and Claims US Patent 9750711, assigned to Kyowa Kirin International Ltd., is a novel patent in the realm of pharmaceuticals, specifically focusing on a composition comprising a biologically active opioid peptide, primarily consisting of the analgesic peptide kyotorphin. This patent provides unique insights into a significant aspect of opioid research, claiming several practical applications, including the treatment of pain and substance addiction. Scope and Background Kyotorphin, a naturally occurring opioid peptide, has long been recognized for its analgesic properties. While research has primarily focused on its therapeutic potential, there is a growing understanding of its advantages over traditional opioid medications. These advantages include lower addictiveness and the potential for reduced opioid-related side effects. Patent 9750711 seeks to capitalize on these findings, proposing a broader scope for the use of kyotorphin and related compounds in both medical treatments and research applications. Key Claims and Covered Subject Matter The patent covers a broad range of claims, encompassing compositions, methods of treatment, and products for reducing opioid use disorder. The inventive concepts are centered around three primary subject matters: Composition for Treating Pain or Substance Use Disorders: The patent claims a novel composition, comprising kyotorphin or a functional analogous peptide, as an effective analgesic or therapeutic agent for addressing pain, particularly chronic pain, as well as substance use disorder. This claim has significant implications for substance abusers who struggle with the debilitating effects of chronic pain-associated withdrawal symptoms. Polymer Compound Containing Opioid Peptide: The patent includes claims for a polymer compound containing kyotorphin or a polymeric derivative of the peptide. These compounds may possess enhanced therapeutic properties, such as more sustained delivery and increased bioavailability of the peptide. Preparation of Active Pharmaceutical Ingredients (APIs) for Use in Injectable Forms: The patent claims processes for producing APIs for injectable formulations using kyotorphin or a peptide derivative, optimized for enhanced product delivery and efficacy. Impact and Future Directions US Patent 9750711 opens up new avenues for research into the efficacy and potential applications of kyotorphin in treating pain and opioid use disorder. Its key takeaways are: The composition offers a well-tolerated, effective option for pain management and substance use disorder treatment. Targeted delivery systems using the compound could help improve therapeutic outcomes and patient compliance. This novel peptide-based composition could revolutionize our treatment approach to addiction and chronic pain. This analysis has evaluated the key points and claims within US Patent 9750711, highlighting the critical aspects of this groundbreaking patent in the pharmaceutical field.

Drugs Protected by US Patent 9,750,711

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Sun Pharm	ABSORICA LD	isotretinoin	CAPSULE;ORAL	211913-001	Nov 5, 2019		RX	Yes	No	9,750,711		Y
Sun Pharm	ABSORICA LD	isotretinoin	CAPSULE;ORAL	211913-002	Nov 5, 2019		RX	Yes	No	9,750,711		Y
Sun Pharm	ABSORICA LD	isotretinoin	CAPSULE;ORAL	211913-003	Nov 5, 2019		DISCN	Yes	No	9,750,711		Y
Sun Pharm	ABSORICA LD	isotretinoin	CAPSULE;ORAL	211913-004	Nov 5, 2019		RX	Yes	No	9,750,711		Y
Sun Pharm	ABSORICA LD	isotretinoin	CAPSULE;ORAL	211913-005	Nov 5, 2019		DISCN	Yes	No	9,750,711		Y
Sun Pharm	ABSORICA LD	isotretinoin	CAPSULE;ORAL	211913-006	Nov 5, 2019		RX	Yes	Yes	9,750,711		Y

Foreign Priority and PCT Information for Patent: 9,750,711

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
India	2827/DEL/2014	Oct 1, 2014

International Family Members for US Patent 9,750,711

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2015326489
Brazil	112017006779
Canada	2963206
European Patent Office	3200877
Japan	2017530149
Mexico	2017004312